858 related articles for article (PubMed ID: 18812421)
21. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
[TBL] [Abstract][Full Text] [Related]
22. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use.
Rönnerdag M; Odlind V
Acta Obstet Gynecol Scand; 1999 Sep; 78(8):716-21. PubMed ID: 10468065
[TBL] [Abstract][Full Text] [Related]
23. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
Wildemeersch D; Janssens D; Vrijens M; Weyers S
Contraception; 2005 Jun; 71(6):465-9. PubMed ID: 15914138
[TBL] [Abstract][Full Text] [Related]
24. Endometrial effects of intrauterine levonorgestrel.
Guttinger A; Critchley HO
Contraception; 2007 Jun; 75(6 Suppl):S93-8. PubMed ID: 17531624
[TBL] [Abstract][Full Text] [Related]
25. The levonorgestrel intrauterine system: the benefits of reduced bleeding.
Cameron IT
Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():27-32. PubMed ID: 11336431
[TBL] [Abstract][Full Text] [Related]
26. Treatment of menorrhagia with an LNG-IUS.
Pakarinen P; Luukkainen T
Contraception; 2007 Jun; 75(6 Suppl):S118-22. PubMed ID: 17531601
[TBL] [Abstract][Full Text] [Related]
27. [Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis].
Deng S; Lang JH; Leng JH; Liu ZF; Sun DW; Zhu L
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):664-8. PubMed ID: 17199919
[TBL] [Abstract][Full Text] [Related]
28. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
29. Trimegestone differentially modulates the expression of matrix metalloproteinases in the endometrial stromal cell.
Wahab M; Taylor AH; Pringle JH; Thompson J; Al-Azzawi F
Mol Hum Reprod; 2006 Mar; 12(3):157-67. PubMed ID: 16556677
[TBL] [Abstract][Full Text] [Related]
30. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis.
Petta CA; Ferriani RA; Abrao MS; Hassan D; Rosa E Silva JC; Podgaec S; Bahamondes L
Hum Reprod; 2005 Jul; 20(7):1993-8. PubMed ID: 15790607
[TBL] [Abstract][Full Text] [Related]
31. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV.
Heikinheimo O; Lehtovirta P; Suni J; Paavonen J
Hum Reprod; 2006 Nov; 21(11):2857-61. PubMed ID: 16880227
[TBL] [Abstract][Full Text] [Related]
32. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
Lukes AS; Reardon B; Arepally G
Fertil Steril; 2008 Sep; 90(3):673-7. PubMed ID: 18001734
[TBL] [Abstract][Full Text] [Related]
33. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
34. Progestin-releasing intrauterine systems.
Luukkainen T; Pakarinen P; Toivonen J
Semin Reprod Med; 2001 Dec; 19(4):355-63. PubMed ID: 11727177
[TBL] [Abstract][Full Text] [Related]
35. Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users.
Li A; Felix JC; Yang W; Xiong DW; Minoo P; Jain JK
Contraception; 2007 Jul; 76(1):57-65. PubMed ID: 17586139
[TBL] [Abstract][Full Text] [Related]
36. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
[TBL] [Abstract][Full Text] [Related]
37. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system.
Wildemeersch D; Rowe PJ
Contraception; 2005 Jun; 71(6):470-3. PubMed ID: 15914139
[TBL] [Abstract][Full Text] [Related]
38. Effect of single post-ovulatory administration of levonorgestrel on gene expression profile during the receptive period of the human endometrium.
Vargas MF; Tapia-Pizarro AA; Henríquez SP; Quezada M; Salvatierra AM; Noe G; Munroe DJ; Velasquez LA; Croxatto HB
J Mol Endocrinol; 2012 Feb; 48(1):25-36. PubMed ID: 22052941
[TBL] [Abstract][Full Text] [Related]
39. Levonorgestrel-releasing intrauterine system: why do some women dislike it?
Daud S; Ewies AA
Gynecol Endocrinol; 2008 Dec; 24(12):686-90. PubMed ID: 19172537
[TBL] [Abstract][Full Text] [Related]
40. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts.
Reid PC; Virtanen-Kari S
BJOG; 2005 Aug; 112(8):1121-5. PubMed ID: 16045528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
